{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:54:48Z","timestamp":1774968888491,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,6]],"date-time":"2019-04-06T00:00:00Z","timestamp":1554508800000},"content-version":"vor","delay-in-days":95,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/j.lrr.2019.04.001","type":"journal-article","created":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T10:43:06Z","timestamp":1555152186000},"page":"21-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy"],"prefix":"10.1016","volume":"11","author":[{"given":"Satoko","family":"Oka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Nohgawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.lrr.2019.04.001_bib0001","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.lrr.2019.04.001_bib0002","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","article-title":"Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma","volume":"30","author":"Katsuya","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lrr.2019.04.001_bib0003","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.lrr.2019.04.001_bib0004","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2014-03-559591","article-title":"Lenalidomide inhibits the proliferation of CLL cells via a cereblon\/p21(WAF1\/Cip1)-dependent mechanism independent of functional p53","volume":"124","author":"Fecteau","year":"2014","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.lrr.2019.04.001_bib0005","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"34","key":"10.1016\/j.lrr.2019.04.001_bib0006","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lrr.2019.04.001_bib0007","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12325-018-0658-4","article-title":"A review of new findings in adult T-cell leukemia-lymphoma: a focus on current and emerging treatment strategies","volume":"35","author":"Hermine","year":"2018","journal-title":"Adv. Ther."},{"issue":"24","key":"10.1016\/j.lrr.2019.04.001_bib0008","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","article-title":"ATL-prognostic index project. Treatment and survival among 1594 patients with ATL","volume":"126","author":"Katsuya","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.lrr.2019.04.001_bib0009","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.bbmt.2013.09.014","article-title":"Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study","volume":"19","author":"Ishida","year":"2013","journal-title":"Biol. Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.lrr.2019.04.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1405204","article-title":"Deep sequencing of the T cell receptor visualizes reconstitution of T cell immunity in mogamulizumab-treated adult T cell leukemia","volume":"7","author":"Shindo","year":"2017","journal-title":"Oncoimmunology"}],"updated-by":[{"DOI":"10.1016\/j.lrr.2022.100308","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000}}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048918300657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048918300657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:07:57Z","timestamp":1761959277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048918300657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":10,"alternative-id":["S2213048918300657"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2019.04.001","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2019.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}